查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1882973

麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测 (2024-2032)

Measles, Mumps, Rubella (MMR) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场成长驱动因子

由于传染病流行率的上升、全球疫苗接种活动的扩大以及主要卫生组织的大力支持，全球麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场正在快速扩张。根据本报告，市场规模预计将在 2024 年成长至 50.6 亿美元，2025 年将成长至 51.7 亿美元，到 2032 年将达到 110.1 亿美元，预测期内复合年增长率 (CAGR) 为 11.4%。 2024年，北美将占最大的市场占有率，达到37.15%，这得益于其健全的公共卫生体系和高疫苗接种率。

麻疹、腮腺炎、德国麻疹 (MMR) 疫苗使用减毒活病毒诱发免疫，预防三种高传染性病毒性疾病：麻疹、腮腺炎和德国麻疹。这些疫苗通常在儿童12个月和4岁时接种两次，已证实具有很高的有效性。根据美国疾病管制与预防中心 (CDC) 2025年1月发布的数据，MMR疫苗第一剂对麻疹的有效率为93%，对腮腺炎的有效率为72%，对德国麻疹的有效率为97%，这支持了其在全球的推广应用。葛兰素史克 (GSK plc)、印度血清研究所 (Serum Institute of India Pvt. Ltd.) 等疫苗生产商加强了研发力道。有限公司和默克公司正在进一步加速市场发展。

市场动态

驱动因素

政府主导的免疫规划是全球麻疹、腮腺炎、德国麻疹 (MMR) 疫苗需求的主要驱动因素。美国和印度等国家已将 MMR 疫苗纳入国家免疫规划，确保符合条件的儿童能够广泛接种。世界卫生组织 (WHO) 和全球疫苗免疫联盟 (Gavi) 等国际组织正透过提供资金和后勤支援来加强这些工作。例如，Gavi 在 2025 年 5 月报告称，在将 MR 疫苗纳入常规免疫规划之前，他们支持了多个国家的麻疹-德国麻疹后续疫苗接种活动。

抑制因子

疫苗犹豫仍是市场成长的最大障碍之一。错误讯息、对副作用的误解以及对医疗保健系统的不信任等因素都会降低疫苗的接受度。根据美国国家生物技术资讯中心 (NCBI) 2023 年 10 月发布的报告，许多家长因担心发烧和注射部位疼痛而避免给孩子接种麻疹、腮腺炎、德国麻疹 (MMR) 疫苗，这表明感知风险对疫苗接种率的影响。

机会

微阵列贴片 (MAP) 等技术创新为开发无针头、耐热且易于接种的 MMR 疫苗提供了巨大潜力。这些技术创新有助于提高疫苗接种依从性，尤其是在医疗资源有限的低收入地区。 2019 年，联合国儿童基金会和世界卫生组织开始与合作伙伴共同开发微阵列贴片，这代表着未来广泛应用的一条充满希望​​的途径。

挑战

保持冷链完整性是一项持续的挑战。 MMR 疫苗对温度波动高度敏感，处理不当会降低疫苗效力并增加浪费。美国疾病管制与预防中心基金会 (CDC Foundation) 2024 年 9 月的报告证实，麻疹疫苗极容易受到温度波动的影响，凸显了许多地区冷链的限制。

市场趋势

影响麻疹、腮腺炎、德国麻疹 (MMR) 疫苗市场的一个关键趋势是，旨在弥补免疫接种缺口的公私合作模式的兴起。这些合作加强了疫苗分发，改善了疫苗物流，并促进了社区参与。根据全球疫苗免疫联盟 (Gavi) 2025 年 5 月发布的数据，2013 年至 2017 年间，该联盟向麻疹和风疹倡议拨款 5,500 万美元，这表明其对疾病控製做出了长期的财务承诺。

细分市场分析

按类型

2024 年，联合疫苗细分市场占主导地位，因为它具有方便、经济高效以及只需一次注射即可预防三种疾病的优点。 2022年6月，葛兰素史克(GSK)的Priorix获得FDA批准，进一步巩固了该细分市场的成长。

依产品划分

2024年，麻疹-腮腺炎-德国麻疹二联疫苗(MMR II)引领市场，这得益于其在美国30年来超过2.31亿剂的销售记录，证明了其在全球范围内长期且可靠的应用。由于获得了广泛的监管批准和强有力的临床证据，PRIORIX预计将快速成长。

依给药途径划分

2024年，皮下注射占最大市占率。这是因为大多数麻疹-腮腺炎-德国麻疹疫苗，包括MMR II和PRIORIX，都获准皮下注射。

依年龄组别划分

由于儿童对麻疹、腮腺炎、德国麻疹 (MMR) 疫苗的高易感性以及该疫苗已深度纳入儿童免疫接种计划，预计 2024 年儿科市场将占最大占有率。

依通路划分

由于各国免疫规划的大规模采购，政府供应商占了市场主导地位。 2021 年，联合国儿童基金会代表 35 个国家采购了 1.81 亿剂 MMR 疫苗。

区域展望

预计 2024 年，北美市场规模将达到 18.8 亿美元，这得益于其强大的免疫基础设施和公共卫生举措。美国凭藉全面的疫苗接种政策和持续的疾病监测，在该地区处于领先地位。由于欧盟/欧洲经济区国家强制接种两剂疫苗，欧洲也维持较高的市场占有率。亚太地区是成长最快的地区，这主要得益于各国疫苗接种计划的扩展以及透过诸如印度全民免疫计划（UIP）等举措实施的免费疫苗接种。拉丁美洲以及中东和非洲地区也呈现稳定成长，这得益于人们免疫意识的提高和医疗保健服务的改善。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家/地区主要疾病的发生率/盛行率（2024 年）
  • 主要公司产品线分析
  • 主要国家疫苗接种覆盖率概述
  • 麻疹、腮腺炎、德国麻疹 (MMR) 疫苗的技术进步
  • 主要公司新产品发布
  • 主要产业趋势，包括併购和合作伙伴关係

第五章：全球麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析、洞察与预测 (2019-2032)

  • 市场分析、洞察与预测 - 按类型划分
    • 单价疫苗
    • 联合疫苗
  • 市场分析、洞察与预测 - 按产品划分
    • MMR II
    • PRIORIX
    • MMR Pro
    • Tresivac
    • 其他
  • 市场分析、洞察与预测 - 按给药途径划分
    • 肌肉注
    • 皮下注射
    • 其他
  • 市场分析、洞察与预测 - 按年龄划分组别
    • 儿科
    • 成人
  • 市场分析、洞察与预测 - 按分销管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东与非洲麻疹-腮腺炎-德国麻疹 (MMR) 疫苗市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • 葛兰素史克 (GSK) plc.
    • 印度血清研究所私人有限公司
    • 默克公司
    • 印度免疫学有限公司
    • Zydus生命科学股份有限公司
    • 武田药品工业株式会社
    • BIOLOGICAL E. LIMITED
    • Invivyd公司
    • 第一三共株式会社
Product Code: FBI113753

Growth Factors of measles, mumps, rubella (MMR) vaccines Market

The global measles, mumps, rubella (MMR) vaccines market is expanding rapidly due to rising infectious disease prevalence, increasing global immunization efforts, and strong support from major health organizations. According to the report, the market size was USD 5.06 billion in 2024, is expected to increase to USD 5.17 billion in 2025, and reach USD 11.01 billion by 2032, exhibiting a CAGR of 11.4% during the forecast period. In 2024, North America held the largest share at 37.15%, driven by robust public health systems and high vaccination coverage.

MMR vaccines protect against three highly contagious viral diseases-measles, mumps, and rubella-using weakened live viruses to induce immunity. Administered in two doses, typically at 12 months and again at 4 years of age, these vaccines demonstrate strong effectiveness. CDC data published in January 2025 shows the first MMR dose is 93% effective against measles, 72% effective against mumps, and 97% effective against rubella, supporting their continued global adoption. Increasing R&D activities by vaccine manufacturers such as GSK plc., Serum Institute of India Pvt. Ltd., and Merck & Co., Inc. further accelerate market progress.

Market Dynamics

Drivers

Government-backed immunization programs are a major driver of global MMR vaccine demand. Countries such as the U.S. and India have integrated MMR into national immunization schedules, ensuring widespread availability for eligible children. Global organizations, including WHO and Gavi, amplify these efforts through financial and logistical support. For example, in May 2025, Gavi reported supporting measles-rubella catch-up campaigns in multiple countries before MR vaccines were added to routine immunization.

Restraints

Vaccine hesitancy remains one of the most significant barriers to market growth. Factors such as misinformation, misconceptions about side effects, and distrust in healthcare systems reduce vaccine acceptance. According to an October 2023 publication by the National Center for Biotechnology Information, many parents avoided MMR vaccination due to concerns about fever and injection-site pain, demonstrating the influence of perceived risks on uptake.

Opportunities

Technological advancements such as microarray patches (MAPs) create significant opportunities for needle-free, thermostable, and easy-to-administer MMR vaccines. These innovations improve compliance, especially in low-income regions with limited healthcare access. UNICEF and WHO began developing microarray patches in collaboration with partners in 2019, offering a strong pathway for future adoption.

Challenges

Maintaining cold chain integrity presents an ongoing challenge. MMR vaccines are extremely sensitive to temperature fluctuations, and improper handling can reduce efficacy and increase wastage. A September 2024 CDC Foundation report confirmed the measles vaccine's high vulnerability to temperature variations, highlighting cold-chain limitations in many regions.

Market Trends

A key trend shaping the MMR vaccine market is the rise in public-private partnerships aimed at addressing immunization gaps. These collaborations enhance distribution, improve vaccine logistics, and strengthen community engagement. Gavi data published in May 2025 showed that USD 55 million was allocated to the Measles & Rubella Initiative between 2013 and 2017, demonstrating long-term financial commitment to disease control.

Segmentation Insights

By Type

The combination vaccine segment dominated in 2024 due to its convenience, cost-effectiveness, and ability to protect against all three diseases through a single injection. FDA approval of GSK's Priorix in June 2022 further strengthened segment growth.

By Product

M-M-R II led the market in 2024, supported by more than 231 million doses sold in the U.S. over 30 years, indicating long-proven global usage. PRIORIX is expected to grow rapidly due to its wide regulatory approvals and strong clinical evidence.

By Route of Administration

The subcutaneous route accounted for the largest share in 2024, as most MMR vaccines-including M-M-R II and PRIORIX-are approved for SC administration.

By Age Group

The pediatric segment held the highest share in 2024 due to heightened susceptibility of children and strong inclusion of MMR in childhood immunization schedules.

By Distribution Channel

Government suppliers dominated due to large-scale procurement for national immunization programs. UNICEF procured 181 million MR vaccine doses in 2021 on behalf of 35 countries.

Regional Outlook

In 2024, North America generated USD 1.88 billion, driven by strong vaccination infrastructure and public health initiatives. The U.S. leads the region with comprehensive immunization policies and continuous disease monitoring. Europe holds a strong share due to mandatory two-dose schedules across EU/EEA countries. Asia Pacific is the fastest-growing region due to expansions of national immunization programs and free vaccine administration under initiatives such as India's Universal Immunization Programme (UIP). Latin America and Middle East & Africa show steady growth supported by rising awareness and improving healthcare access.

Conclusion

Expanding from USD 5.06 billion in 2024 to USD 11.01 billion by 2032, the MMR vaccines market is set for strong growth through improved awareness, technological innovation, public-private collaborations, and strengthened immunization programs worldwide.

Segmentation By Type

  • Standalone
  • Combination

By Product

  • M-M-R II
  • PRIORIX
  • M-M-RvaxPro
  • Tresivac
  • Others

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Others

By Age Group

  • Adult
  • Pediatric

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Overview: Immunization Coverage, By Key Countries
  • 4.4. Technological Advancements in the MMR Vaccines
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Standalone
    • 5.1.2. Combination
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. M-M-R II
    • 5.2.2. PRIORIX
    • 5.2.3. M-M-RvaxPro
    • 5.2.4. Tresivac
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Intramuscular
    • 5.3.2. Subcutaneous
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatrics
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Standalone
    • 6.1.2. Combination
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. M-M-R II
    • 6.2.2. PRIORIX
    • 6.2.3. M-M-RvaxPro
    • 6.2.4. Tresivac
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Intramuscular
    • 6.3.2. Subcutaneous
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatrics
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Standalone
    • 7.1.2. Combination
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. M-M-R II
    • 7.2.2. PRIORIX
    • 7.2.3. M-M-RvaxPro
    • 7.2.4. Tresivac
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Intramuscular
    • 7.3.2. Subcutaneous
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatrics
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Standalone
    • 8.1.2. Combination
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. M-M-R II
    • 8.2.2. PRIORIX
    • 8.2.3. M-M-RvaxPro
    • 8.2.4. Tresivac
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Intramuscular
    • 8.3.2. Subcutaneous
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatrics
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Standalone
    • 9.1.2. Combination
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. M-M-R II
    • 9.2.2. PRIORIX
    • 9.2.3. M-M-RvaxPro
    • 9.2.4. Tresivac
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Intramuscular
    • 9.3.2. Subcutaneous
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatrics
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Standalone
    • 10.1.2. Combination
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. M-M-R II
    • 10.2.2. PRIORIX
    • 10.2.3. M-M-RvaxPro
    • 10.2.4. Tresivac
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Intramuscular
    • 10.3.2. Subcutaneous
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatrics
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Serum Institute of India Pvt. Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Indian Immunologicals Limited
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Lifesciences Limited
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Takeda Pharmaceutical Company Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BIOLOGICAL E. LIMITED
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Invivyd, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Daiichi Sankyo Company, Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 16: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 17: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 19: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 20: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 22: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 23: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 26: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 28: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 29: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 32: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 34: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2019-2032
  • Table 35: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024 & 2032
  • Figure 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 13: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 14: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 15: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 16: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country, 2024
  • Figure 20: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 21: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 22: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 25: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 26: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 27: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 28: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 33: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 34: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 37: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 38: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 39: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 40: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 45: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 46: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 49: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 50: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 51: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 52: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 57: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2024
  • Figure 58: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 61: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 62: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2024 & 2032
  • Figure 63: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2024
  • Figure 64: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Measles, Mumps, Rubella (MMR) Vaccines Market Share (%), By Company, 2024